Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 113.376 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin/metformin maple (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin/metformin mylan (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitagliptin/metformin maple (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitagliptin/metformin mylan (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 28.344 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Australia - English - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 28.344 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptin hydrochloride monohydrate 28,343 mg - eq. sitagliptin 25 mg - film-coated tablet - 25 mg - sitagliptin hydrochloride monohydrate 28.343 mg - sitagliptin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptin hydrochloride monohydrate 56,685 mg - eq. sitagliptin 50 mg - film-coated tablet - 50 mg - sitagliptin hydrochloride monohydrate 56.685 mg - sitagliptin